250
Registered trials
114
Recruiting
119
Completed trials
106
Sponsors
26
Countries
Phase III:
112
Phase II/III:
15
Phase II:
88
Phase I/II:
11
Phase III/IV:
3
Phase IV:
8
Phase I:
1
Phase I (Other):
2
Phase I (FiH):
10
Oversight events:
7 serious breaches
34 temporary halts
7 urgent safety measures
9 unexpected events
4 corrective measures
across 27 trials
View oversight register →
Indications tested
Non-small cell lung cancer
20
Non-small cell lung cancer metastatic
13
Ovarian cancer
12
Fallopian tube cancer
11
Triple negative breast cancer
9
Non-small cell lung cancer stage III
9
Non-small cell lung cancer stage IV
8
Non-small cell lung cancer stage IIIB
7
Ovarian epithelial cancer
7
Breast cancer
7
Hormone receptor positive HER2 negative breast cancer
5
Non-small cell lung cancer stage IIIA
5
Sponsors using this IMP
Merck Sharp & Dohme LLC
36
AstraZeneca AB
25
Bristol-Myers Squibb Services Unlimited Company
8
Intergroupe Francophone De Cancerologie Thoracique
8
Unicancer
8
Gilead Sciences Inc.
7
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
7
F. Hoffmann-La Roche AG
5
Karolinska University Hospital
5
Regeneron Pharmaceuticals Inc.
5
BioNTech SE
4
Bristol Myers Squibb International Corporation
4
All trials — page 6
250 total-
HARMONi-3 Ended
Showing 121–144 of 250 trials